

PRODUCT INFORMATION

Clone ID	DMC484
Target	CDH1
Synonyms	Arc-1; BCDS1; CD324; CDHE; ECAD; LCAM; UVO
Host Species	Rabbit
Description	Biotinylated Anti-CDH1 antibody(DMC484); IgG1 Chimeric mAb
Delivery	2-3 weeks
Uniprot ID	P12830
IgG type	Rabbit/Human Fc chimeric IgG1
Clonality	Monoclonal
Reactivity	Human
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Purification	Purified from cell culture supernatant by affinity chromatography
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	This gene encodes a classical cadherin of the cadherin superfamily. Alternative splicing results in multiple transcript variants; at least one of which encodes a preproprotein that is proteolytically processed to generate the mature glycoprotein. This calcium-dependent cell-cell adhesion protein is comprised of five extracellular cadherin repeats; a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric; breast; colorectal; thyroid and ovarian cancer. Loss of function of this gene is thought to contribute to cancer progression by increasing proliferation; invasion; and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. This gene is present in a gene cluster with other members of the cadherin family on chromosome 16. [provided by RefSeq; Nov 2015]
Usage	Research use only
Conjugate	Biotinylated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

